 Valeant Pharmaceuticals International Inc said its secondquarter profit and sales climbed amid strong growth in almost all of its businesses as the company again made a case to buy Botox maker Allergan Inc But Valeant lowered its revenue and earningspershare guidance for the year to reflect the sale of its facialinjectables business among other items Valeant
  